Gastrointestinal motility disorders are managed pharmacologically through several mechanistic drug classes: cholinomimetics and acetylcholinesterase inhibitors that increase gut motility via cholinergic stimulation, dopamine D2 receptor antagonists that increase bowel transit by blocking dopaminergic inhibition (also acting on the brain's emetic center as antiemetics), and motilin receptor agonists that directly stimulate motilin receptors to enhance gastric emptying. Laxatives are classified by mechanism—bulk-forming (increasing stool bulk via fiber activation), stool softeners, osmotic agents (drawing water into the stool), stimulants (irritating the bowel), chloride channel activators, and opioid receptor antagonists (reversing opioid-induced constipation)—while antidiarrheal agents work via opioid receptor agonism (reducing motility) or via adsorption/binding of toxins and fluid in the gut lumen. This is a topic within gastrointestinal pharmacology, situated within the broader framework of autonomic nervous system pharmacology governing gut motility.
Gastrointestinal motility disorders are managed pharmacologically through several mechanistic drug classes: cholinomimetics and acetylcholinesterase inhibitors that increase gut motility via choliner…